Bayer plans to regroup its chemicals operations

Article Abstract:

Germany-based Bayer AG intends to reorganize its chemicals ventures to advance its growth opportunities in the field starting Jan. 1, 1998. The company believes that the undertaking will cement Bayer's position as the premier integrated chemicals and health-care group. The reorganization will create a three new groups, the first of which consolidates basic and fine chemicals segments of the current inorganics and organic chemical business groups. A new unit called performance chemicals will be formed for chemicals for the leather and paper industries, material protection items, ion-exchange resins, textile chemicals and polymer additives. Meanwhile, the third group involves expanding Bayer's polymers business.

Comment:

Intends to reorganize its chemicals ventures to advance its growth opportunities in the field starting 1/1/98

---

Daimler debates building M-Class in Chrysler plant

Article Abstract:

Daimler-Benz AG is considering the expansion of the production of its US-built, M-Class off-roader at a Chrysler Corp. facility to reduce the long waiting lists for the popular vehicle. A decision whether to use the Chrysler facility will be made upon the completion of the two companies' merger in Sep. 1998. Earlier, Daimler reported plans of increasing M-Class production to 80,000 from about 65,000 cars in its Alabama plant. The M-Class, which went on sale in Europe at the end of March 1998, competes with the Jeep Cherokee and Grand Cherokee models of Chrysler.

Comment:

Is considering the expansion of the production of its US-built, M-Class off-roader at a Chrysler Corp facility

Motor Vehicles & Parts, Transportation Equipment Manufacturing, Daimler-Benz AG

---

Bayer becomes partner with Morphosys; German firms target monoclonal anitbodies

Article Abstract:

This article discusses the two-year agreement between Bayer AG and Morphosys AG to work on the development of synthetic molecules which mimic natural antibodies. The companies hope to develop treatments for cancer, asthma and other diseases.

Biological Product (except Diagnostic) Manufacturing, Strategic alliances, Monoclonal Antibodies for Therapeutics, Therapeutics, Contracts, Biological products industry, Chemical industry, Monoclonal antibodies, MorphoSys AG

Similar abstracts:

• Abstracts: Renters choice to acquire Thorn's U.S. operations. Investcorp deal boosts shares of Jostens 31%. Milken, Ellison bolster their presence in consulting with another acquisition
• Abstracts: Media group wins two court battles. Nilesat to end TV monopoly? Prima wants primetime
• Abstracts: Thomson-CSF moves to private sector. Philips expects a dismal year for global electronics sector. PPR launches e-commerce initiative

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.